Significance of cell cycle for wound stratification in clinical trials: analysis of a pressure @entity1066 clinical trial utilizing cyclin D/ XXXX .

@entity1 @entity1066 @entity8985
During the past 5 years, progress in the treatment of pressure ulcers appears to have reached a plateau. Several factors in the design of recent clinical studies may have contributed to this situation. These factors include the criteria chosen for @entity1 selection, small sample size, and lack of a concisely defined final clinical outcome. Hunt noted that wound stratification according to a @entity1 's physiological characteristics may be a key to quantifying differences among clinical treatments. To address this issue, we examined the expression of cyclin D/ @entity8985 in pressure @entity1066 fibroblasts taken from tissues during a recent clinical trial. The treatment groups included @entity1 treated with the following regimens: placebo, granulocyte macrophage-colony stimulating factor alone, basic fibroblast growth factor alone, or granulocyte macrophage-colony stimulating factor and basic fibroblast growth factor given in sequence. Immunocytochemical colocalization of cyclin D and @entity8985 showed that, before the initial treatment began, @entity1 were distributed disproportionately among treatment subgroups in regards to the initial expression of these markers. For example, we found that compared with other subgroups, @entity1066 fibroblasts in the basic fibroblast growth factor treatment group showed a much lower expression of cyclin D/ @entity8985 at day 0. However, this group exhibited higher levels of expression of this complex after 35 days of treatment. This study shows that measurement of cyclin D/ @entity8985 expression permits more accurate stratification of @entity1 within treatment subgroups, measurement of a cell's ability to detect the presence of functional cytokines, identification of area(s) of failure within the G1 of the cell cycle, and a basis for critical evaluation of various treatments.
